CorMedix Inc. CRMD
4.84 USD -0.46 (-8.68%)
At closeNov 12, 2026, 5:49 PM EST
4.86 +0.02 +0.42%
After hours · Nov 12, 5:49 PM ET
4.82 Day range 5.49
4.84 52-week range 12.73
- YTD
- -58.38%
- 1 year
- -57.62%
News
seekingalpha.com CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
marketbeat.com What CorMedix (CRMD) Said on Its Q3 Earnings Call CorMedix NASDAQ: CRMD reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron…
zacks.com CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.
benzinga.com Cormedix Q3 2026 Earnings Call Transcript Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57…
benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $337.061 million estimate.
globenewswire.com Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company…
benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
marketbeat.com CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in…
benzinga.com Needham Maintains Buy on Cormedix, Raises Price Target to $14 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.- benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…
globenewswire.com CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026,…
zacks.com Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Needham Maintains Buy on Cormedix, Lowers Price Target to $12 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.
benzinga.com CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4 CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325…
globenewswire.com CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to…
defenseworld.net CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial Analysis CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027 CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO®…
globenewswire.com Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New…- benzinga.com Actinium Pharmaceuticals Appoints Dr. Matt David As CFO Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…
prnewswire.com Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
zacks.com CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better…
benzinga.com Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15 Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.
zacks.com Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
globenewswire.com CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for…
zacks.com CorMedix (CRMD) Upgraded to Buy: Here's Why CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
zacks.com CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
benzinga.com CorMedix Stock Jumps on Strong DefenCath Sales CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
benzinga.com Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros…
benzinga.com Full Transcript: Cormedix Q2 2026 Earnings Call On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…- benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.
benzinga.com Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after reporting Q4 losses. Other stocks also lower in pre-market.
benzinga.com RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.
benzinga.com Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings 
benzinga.com Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday - benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Top Stocks With Earnings This Week: Plug, Oklo, Circle And More Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.
benzinga.com Hedge Fund Elliott Management's Q2 Moves Include Positions Tied To S&P 500, Nasdaq, Nvidia (CORRECTED) Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major indexes and tech leaders like Nvidia while exiting several prior holdings.